Back to News
Market Impact: 0.25
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
Source: Business Wire
Legal & Litigation
Capricor Therapeutics faces a pending securities-fraud class action following a 64% stock-price decline. The notice urges investors to contact BFA Law before the September 28 deadline, highlighting elevated litigation and investor-risk concerns for Capricor.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.65
Ticker Sentiment
CAPR-0.95
More News
- People Inc earnings up next after MGM deal collapse
- United Therapeutics’ Rothblatt sells $4.7 million in stock
- TechCrunch Mobility: A new, bigger AV boom is here
- Alaska Sen. Sullivan says he'll accept election results, slams Peltola campaign’s reported recruitment of 2nd Sullivan
- Sullivan vows to honour Alaska race outcome, US judge dismisses DOJ lawsuit
- Judge says xAI must face NAACP lawsuit on data center pollution